Pub Date : 2022-07-01Epub Date: 2022-07-21DOI: 10.4155/ppa-2022-0018
Yali Friedman
A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.
{"title":"Six drugs facing key patent expirations and potential generic entry from May to June 2022.","authors":"Yali Friedman","doi":"10.4155/ppa-2022-0018","DOIUrl":"https://doi.org/10.4155/ppa-2022-0018","url":null,"abstract":"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 4","pages":"127-129"},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recent update on drug patent linkage system in China.","authors":"Weiwei Han","doi":"10.4155/ppa-2022-0012","DOIUrl":"https://doi.org/10.4155/ppa-2022-0012","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42932865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.
{"title":"Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry.","authors":"Sandro G Viveiros Rosa, W. C. Santos","doi":"10.4155/ppa-2021-0023","DOIUrl":"https://doi.org/10.4155/ppa-2021-0023","url":null,"abstract":"By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44349785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
与药物和医学研发相关的专利文献中值得注意的最新进展的快照。
{"title":"Patent highlights October-November 2021.","authors":"H. Mucke","doi":"10.4155/ppa-2022-0003","DOIUrl":"https://doi.org/10.4155/ppa-2022-0003","url":null,"abstract":"A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45317231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-01Epub Date: 2022-07-21DOI: 10.4155/ppa-2022-0006
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
与制药和医学研究与开发相关的专利文献中值得注意的最新发展概况。
{"title":"Patent highlights December 2021-January 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0006","DOIUrl":"https://doi.org/10.4155/ppa-2022-0006","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 3","pages":"89-96"},"PeriodicalIF":1.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40612852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-01Epub Date: 2022-07-21DOI: 10.4155/ppa-2022-0005
Viridiana I Flores-Quiroz, Lino Zumaquero-Ríos, Martin Perez-Santos
American trypanosomiasis is a neglected tropical disease and an endemic problem in 21 Latin American countries, whose treatment relies on only two US FDA-approved drugs: benznidazole and nifurtimox. Patent literature reveals vital information on new trends in therapies for various diseases, including Chagas disease. The authors used the patent databases of the world's major patent offices to generate an overview of patent trends related to the treatment of Chagas disease. A total of 50 patent families were collected and grouped as 'small molecules', 'pharmaceutical compositions of known compounds' and vaccines. From the results and interpretation, it can be concluded that the treatment of Chagas disease receives little attention in the field of patents and that the upward trend is minimal.
{"title":"Pharmaceutical agents for the treatment of Chagas disease: patenting trends in the 2016-2021 period.","authors":"Viridiana I Flores-Quiroz, Lino Zumaquero-Ríos, Martin Perez-Santos","doi":"10.4155/ppa-2022-0005","DOIUrl":"https://doi.org/10.4155/ppa-2022-0005","url":null,"abstract":"<p><p>American trypanosomiasis is a neglected tropical disease and an endemic problem in 21 Latin American countries, whose treatment relies on only two US FDA-approved drugs: benznidazole and nifurtimox. Patent literature reveals vital information on new trends in therapies for various diseases, including Chagas disease. The authors used the patent databases of the world's major patent offices to generate an overview of patent trends related to the treatment of Chagas disease. A total of 50 patent families were collected and grouped as 'small molecules', 'pharmaceutical compositions of known compounds' and vaccines. From the results and interpretation, it can be concluded that the treatment of Chagas disease receives little attention in the field of patents and that the upward trend is minimal.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 3","pages":"97-110"},"PeriodicalIF":1.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-01Epub Date: 2022-07-21DOI: 10.4155/ppa-2022-0001
Chetan D Sabanis, Bharathi R Kannan, Ramesh Joga, Simran, Sandeep Kumar, Neeraj Kumar
Conventional cancer therapies are associated with toxicity toward healthy cells, which need to be addressed by novel therapeutic approaches. US2021/0230592 patent application discloses a carbon nanotube-based approach for tumor targeting, wherein a self-assembling single-wall nanotube complex has been developed and functionalized to deliver a molecule to a cancerous cell. The radiolabeled nanotubes exhibited markedly reduced toxicity as they did not depict any 'over toxicity' up to radioactivity value of 1350 nCi. The single-wall carbon nanotube conjugates were covalently connected to several chelators, therapeutic or diagnostic radionuclides, and showed promising results in the effective cancer management. Besides, this invention with further modifications paves an ideal pathway to researchers in effective diagnosis and treatment of cancer.
{"title":"Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting.","authors":"Chetan D Sabanis, Bharathi R Kannan, Ramesh Joga, Simran, Sandeep Kumar, Neeraj Kumar","doi":"10.4155/ppa-2022-0001","DOIUrl":"https://doi.org/10.4155/ppa-2022-0001","url":null,"abstract":"<p><p>Conventional cancer therapies are associated with toxicity toward healthy cells, which need to be addressed by novel therapeutic approaches. US2021/0230592 patent application discloses a carbon nanotube-based approach for tumor targeting, wherein a self-assembling single-wall nanotube complex has been developed and functionalized to deliver a molecule to a cancerous cell. The radiolabeled nanotubes exhibited markedly reduced toxicity as they did not depict any 'over toxicity' up to radioactivity value of 1350 nCi. The single-wall carbon nanotube conjugates were covalently connected to several chelators, therapeutic or diagnostic radionuclides, and showed promising results in the effective cancer management. Besides, this invention with further modifications paves an ideal pathway to researchers in effective diagnosis and treatment of cancer.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 3","pages":"111-117"},"PeriodicalIF":1.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40541575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shubhangi Gupta, H. Buttar, Ginpreet Kaur, H. Tuli
Baicalein is a medicinally important flavonoid present in Scutellaria baicalensis, which has numerous biological benefits like anti-oxidant, anti-inflammatory, antihepatotoxicity, anticancer properties, etc. Recent studies have revealed that baicalein is an efficient antihepatoma agent and has the strongest antiproliferative effect toward cancerous bladder cell lines, and suppression of cell cycle progression in prostate cancer cells. This natural substance has a high commercial value because it strengthens the heart and cerebral vessels and protects the nervous system and also reduces diabetes and diabetic complications. In addition, baicalein is known to decrease inflammatory markers such as IL-1β, IL-6 and TNF-α. In this review, we have attempted to compile the list of recent therapeutic patents of baicalein used for treating different disorders.
{"title":"Baicalein: promising therapeutic applications with special reference to published patents.","authors":"Shubhangi Gupta, H. Buttar, Ginpreet Kaur, H. Tuli","doi":"10.4155/ppa-2021-0027","DOIUrl":"https://doi.org/10.4155/ppa-2021-0027","url":null,"abstract":"Baicalein is a medicinally important flavonoid present in Scutellaria baicalensis, which has numerous biological benefits like anti-oxidant, anti-inflammatory, antihepatotoxicity, anticancer properties, etc. Recent studies have revealed that baicalein is an efficient antihepatoma agent and has the strongest antiproliferative effect toward cancerous bladder cell lines, and suppression of cell cycle progression in prostate cancer cells. This natural substance has a high commercial value because it strengthens the heart and cerebral vessels and protects the nervous system and also reduces diabetes and diabetic complications. In addition, baicalein is known to decrease inflammatory markers such as IL-1β, IL-6 and TNF-α. In this review, we have attempted to compile the list of recent therapeutic patents of baicalein used for treating different disorders.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42953257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Slack channels are sodium-activated potassium channels that are encoded by the KCNT1 gene. Several KCNT1 gain of function mutations have been linked to malignant migrating partial seizures of infancy. Quinidine is an anti-arrhythmic drug that functions as a moderately potent inhibitor of Slack channels; however, quinidine use is limited by its poor selectivity, safety and pharmacokinetic profile. Slack channels represent an interesting target for developing novel therapeutics for the treatment of malignant migrating partial seizures of infancy and other childhood epilepsies; thus, ongoing efforts are directed toward the discovery of small-molecules that inhibit Slack currents. This review summarizes patent applications published in 2020-2021 that describe the discovery of novel small-molecule Slack inhibitors.
{"title":"Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies.","authors":"Alshaima'a M Qunies, Kyle A Emmitte","doi":"10.4155/ppa-2022-0002","DOIUrl":"https://doi.org/10.4155/ppa-2022-0002","url":null,"abstract":"Slack channels are sodium-activated potassium channels that are encoded by the KCNT1 gene. Several KCNT1 gain of function mutations have been linked to malignant migrating partial seizures of infancy. Quinidine is an anti-arrhythmic drug that functions as a moderately potent inhibitor of Slack channels; however, quinidine use is limited by its poor selectivity, safety and pharmacokinetic profile. Slack channels represent an interesting target for developing novel therapeutics for the treatment of malignant migrating partial seizures of infancy and other childhood epilepsies; thus, ongoing efforts are directed toward the discovery of small-molecules that inhibit Slack currents. This review summarizes patent applications published in 2020-2021 that describe the discovery of novel small-molecule Slack inhibitors.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 2","pages":"45-56"},"PeriodicalIF":1.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260495/pdf/ppa-11-45.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10810199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-02-03DOI: 10.4155/ppa-2021-0025
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
与制药和医学研究与开发相关的专利文献中值得注意的最新发展概况。
{"title":"Patent highlights August-September 2021.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2021-0025","DOIUrl":"https://doi.org/10.4155/ppa-2021-0025","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 1","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39758418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}